For your patients, every scar is a victory

transplant_woman

Protect every transplant milestone with high-precision monitoring

A recipient's journey doesn't stop at transplantation; protecting the donated graft or organ is essential to their successful recovery.

Post-transplant immunosuppressive regimens are necessary for preventing organ rejection, but they can also increase the risk of opportunistic infections.

Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and BK Virus (BKV) are three of the pathogens associated with significant morbidity and mortality in transplant recipients.1

These infections can be introduced through the donor organ or re-activated after surgery. By regularly monitoring viral load, care teams can identify possible infections early and better decide on an appropriate management plan.

Transplant map

Standardization is the key to care

A transplant patient’s journey often spans several healthcare facilities, including transplant centers far away from the care of their local specialist. In addition, these sites may not use the same testing methodologies, making it difficult to compare viral load results. This can be further complicated if some sites do not report results using the World Health Organization (WHO) International Standards.

Furthermore, growing pressure to reduce turnaround time means that laboratories need to reduce testing complexity. One solution is to shift away from laboratory developed tests (LDTs) and adopt more standardized workflows. This approach enables laboratories to deliver more uniform results with consistent reporting, empowering clinicians to make faster, clearer decisions.

See why result standardization is important for patient follow-up

Chief Medical Officer at Roche Molecular Diagnostics, Alexandra Valsamkis, discusses the importance of standardized assays.

Standardized results can improve care

Join our transplant specialist community for the latest insights.

Laboratory employee working in molecular laboratory

Establish harmonization across care sites by partnering with the transplant IVD molecular testing market leader2

To optimize viral load monitoring and elevate patient care, Roche offers the first FDA-cleared and approved molecular transplant portfolio - The cobas® CMV, cobas® EBV and cobas® BKV tests.

These critical transplant viral tests can both be run from a single patient sample on the fully automated cobas® 5800, 6800, or 8800 system, quickly providing trusted results in a streamlined workflow. Ready-to-use reagents and controls are calibrated to WHO International Standards, enabling comparison of the results across multiple healthcare institutions.

Roche has a robust, comprehensive transplant portfolio spanning serology, molecular and tissue diagnostics to enable confident decision making—all to help protect a second chance in life. 

References

  1. Smith TF, Espy MJ, Mandrekar J, Jones MF, Cockerill FR, Patel R. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45(8):1056-1061.
  2. Data on file at Roche.